^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    IDE397

    i
    Other names: IDE397, GSK4362676, GSK’676, GSK676, GSK 676, GSK 4362676, GSK-4362676, IDE 397, IDE-397
    Company:
    Ideaya Biosci
    Drug class:
    MAT2A inhibitor
    Related drugs:
    20d
    A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=260, Recruiting, IDEAYA Biosciences | Not yet recruiting --> Recruiting
    Enrollment open
    |
    MTAP (Methylthioadenosine Phosphorylase)
    |
    MTAP deletion
    |
    IDE397
    26d
    MTAP Deletion in Oncogenesis: A Synthetic Lethality Scenario. (PubMed, Cancer Res)
    MTA-cooperative PRMT5 inhibitors such as BMS-986504/MRTX1719 and AMG 193 target the PRMT5-MTA complex, while inhibitors of the SAM synthetase methionine adenosyl transferase 2A (MAT2A), such as IDE397, deprive PRMT5 of its methyl donor SAM. In this review article, we summarize the mechanisms of action, preclinical data, and clinical data available thus far for these novel classes of oncology precision medicine and discuss potential future directions relevant to MTAP deletion as a promising synthetic lethal vulnerability for cancer therapy.
    Journal
    |
    MTAP (Methylthioadenosine Phosphorylase) • MAT2A (Methionine Adenosyltransferase 2A)
    |
    MTAP deletion
    |
    BMS‐986504 • IDE397 • AMG 193
    2ms
    A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=260, Not yet recruiting, IDEAYA Biosciences
    New P1 trial
    |
    IDE397
    6ms
    A Phase 1/2 Study of AMG 193 in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors (clinicaltrials.gov)
    P1/2, N=53, Active, not recruiting, Amgen | Trial completion date: Aug 2025 --> Jan 2026 | Trial primary completion date: Aug 2025 --> Jan 2026
    Trial completion date • Trial primary completion date
    |
    MTAP (Methylthioadenosine Phosphorylase)
    |
    MTAP deletion
    |
    IDE397 • AMG 193
    11ms
    A Phase 1/2 Study of AMG 193 in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors (clinicaltrials.gov)
    P1/2, N=53, Active, not recruiting, Amgen | Recruiting --> Active, not recruiting | N=184 --> 53 | Trial completion date: Feb 2027 --> Aug 2025
    Enrollment closed • Enrollment change • Trial completion date
    |
    MTAP (Methylthioadenosine Phosphorylase)
    |
    MTAP deletion
    |
    IDE397 • AMG 193
    1year
    A Phase 1/2 Study of AMG 193 in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors (clinicaltrials.gov)
    P1/2, N=184, Recruiting, Amgen | Trial completion date: Sep 2027 --> Feb 2027 | Trial primary completion date: Mar 2026 --> Aug 2025
    Trial completion date • Trial primary completion date
    |
    MTAP (Methylthioadenosine Phosphorylase)
    |
    MTAP deletion
    |
    IDE397 • AMG 193
    over1year
    A Phase 1/2 Study of AMG 193 in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors (clinicaltrials.gov)
    P1/2, N=184, Recruiting, Amgen | Trial completion date: Dec 2026 --> Sep 2027
    Trial completion date • Combination therapy • Metastases
    |
    MTAP (Methylthioadenosine Phosphorylase)
    |
    MTAP deletion
    |
    IDE397 • AMG 193
    over1year
    A Phase 1/2 Study of AMG 193 in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors (clinicaltrials.gov)
    P1/2, N=184, Recruiting, Amgen | Trial completion date: Aug 2026 --> Dec 2026 | Trial primary completion date: Nov 2025 --> Mar 2026
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    MTAP (Methylthioadenosine Phosphorylase)
    |
    MTAP deletion
    |
    IDE397 • AMG 193
    over1year
    A Phase 1/2 Study of AMG 193 in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors (clinicaltrials.gov)
    P1/2, N=184, Recruiting, Amgen | Trial completion date: Jul 2026 --> Dec 2026
    Trial completion date • Combination therapy • Metastases
    |
    MTAP (Methylthioadenosine Phosphorylase)
    |
    IDE397 • AMG 193
    over1year
    Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion (clinicaltrials.gov)
    P1, N=180, Recruiting, IDEAYA Biosciences | N=130 --> 180 | Trial completion date: Jun 2024 --> Mar 2027 | Trial primary completion date: Dec 2023 --> Dec 2026
    Enrollment change • Trial completion date • Trial primary completion date • Metastases
    |
    MTAP (Methylthioadenosine Phosphorylase)
    |
    MTAP deletion
    |
    paclitaxel • docetaxel • Trodelvy (sacituzumab govitecan-hziy) • IDE397
    2years
    Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion (clinicaltrials.gov)
    P1, N=130, Recruiting, IDEAYA Biosciences | N=382 --> 130
    Enrollment change
    |
    MTAP (Methylthioadenosine Phosphorylase)
    |
    MTAP deletion
    |
    paclitaxel • docetaxel • IDE397
    over2years
    A Phase 1/2 Study of AMG 193 in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors (clinicaltrials.gov)
    P1/2, N=184, Recruiting, Amgen | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    MTAP (Methylthioadenosine Phosphorylase)
    |
    MTAP deletion
    |
    IDE397 • AMG 193